Method of inhibiting osteoclast-mediated bone resorption by administration of N-heterocyclicalkyl-substituted phenyl derivatives

Abstract

Compounds of the general formula ##STR1## Y is an integer of from 0 to 6 is chosen from: O, SO.sub.2, --CONH--, --NHCO--, --CH2-- or ##STR2## R.sup.1 is substituted or unsubstituted mono- or polycyclic saturated hetero-cyclic ring system having 1, 2 or 3 heteroatoms where said heteroatoms are independently chosen from N, O and S and said substituents are chosen from the group comprising R.sup.2 ; R.sup.2 is C.sub.1-6 alkyl, aryl C.sub.0-6 alkyl, hydroxy C.sub.0-6 alkyl, C.sub.1-6 alkoxy C.sub.0-6 alkyl, carboxy C.sub.0-6 alkyl oxo, halogen, CF.sub.3, C.sub.0-4 alkylamino-C.sub.0-6 alkyl or C.sub.0-4 dialkylamino-C.sub.0-6 alkyl; R.sup.3 is C.sub.1-8 alkyl or cycloalkyl, aryl C.sub.0-4 alkyl, hydroxy C.sub.0-4 alkyl C.sub.1-4 alkyloxy C.sub.0-4 alkyl, carboxy C.sub.0-4 alkyl, halogen, CF.sub.3 or hydrogen; R.sup.4 is hydrogen, C.sub.1-6 alkyl, aryl C.sub.0-4 alkyl or C.sub.1-6 alkylcarbonyloxymethyl; and R.sup.5 is C.sub.1-6 alkyl, aryl C.sub.0-4 alkyl or heterocycly C.sub.0-4 alkyl and the pharmaceutically acceptable salts thereof; are used in a method of treating osteoporosis by inhibiting the bone resorption activity of osteoclasts.

Dependencies are inferred from the claim text.